Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XTNT Analyst Upgrades & Downgrades History
Date Research Firm Action From To
Oct 16, 2008 Brean Murray Initiated Buy
Jan 28, 2008 Cowen & Co Initiated Outperform
Dec 20, 2007 Barrington Research Initiated Outperform
Apr 17, 2007 Merriman Curhan Ford Initiated Buy
Mar 21, 2007 Cowen & Co Initiated Outperform
Mar 13, 2007 Piper Jaffray Initiated Outperform
Mar 13, 2007 RBC Capital Mkts Initiated Outperform
Mar 13, 2007 Lazard Capital Initiated Buy
XTNT analyst targets ~
Analyst Opinion Get Analyst Opinion for:
Recommendation Summary*
Mean Recommendation (this week): 1.8
Mean Recommendation (last week): 1.8
Change: 0.0
* (Strong Buy) 1.0 - 5.0 (Sell)
Price Target Summary
Mean Target: 8.75
Median Target: 9.50
High Target: 10.00
Low Target: 6.00
No. of Brokers: 4
XTNT HUGE FDA News Xtant Medical Announces FDA Clearance of the Xspan(TM) Laminoplasty Fixation System
7:30 AM ET 3/30/16 | GlobeNewswire
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, received FDA clearance of the Xspan(TM) Laminoplasty Fixation System.
About the Xspan(TM) Laminoplasty Fixation System
The Xspan(TM) System represents the latest generation of laminoplasty fixation. Spinal laminoplasty is a surgical procedure performed to remove pressure from the spinal cord. Unlike a laminectomy, where the entire lamina is removed, only an opening or window is made on one side of the lamina to alleviate the compression of the spinal cord. The lamina is then restructured by a small plate which allows the spinal canal to increase in size without losing stability or movement in the vertebrae. This procedure can be completed at single or multiple levels.
The Xspan(TM) Laminoplasty Fixation System is intended for use in the lower cervical and upper thoracic spine (C3-T3). "We are very pleased to have received clearance for Xspan," stated Dr. David Kirschman, CSO, EVP, and Director of Xtant Medical. "This system will allow Xtant Medical to further differentiate itself from the competition and will better serve the growing needs of our surgeon partners."
Xtant Medical estimates the world wide market for laminoplasty at $110M and growing. Xspan will be available to a limited number of key surgeons in the second fiscal quarter of 2016, with a larger general release to follow later in 2016.
About Xtant Medical Holdings
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
BONE changed to XTNT and moved to NYSE:
http://ih.advfn.com/p.php?pid=nmona&article=68935477&symbol=BONE
Might wake up today. We'll see. FDA approval of their BONE putty! OS 7millie as of July 15th. On watch bro.
Bacterin International Holdings Inc. changed to Xtant Medical Holdings Inc.:
http://otce.finra.org/DLSymbolNameChanges
BONE delisted from AMEX to the OTC:
http://otce.finra.org/DLAdditions
BONE up over 29% and halted trading!
I got out @ 3.94!!!
BONE up almost 9.5% today!
• Solid foundation for accelerating growth in 2015 and beyond
• Growing team of Field Sales assets
• New Product Pipeline
• Path to EBITDA profitability and positive cash flow
4th Consecutive Quarter of Year-over-Year Growth
• 3Q14 Revenues increased 6.6% over 3Q13
• Four consecutive quarters of YoY growth
• Improving Gross Profit and Gross Margins
• Narrowing Operating Loss
• Investing in New Products and Sales Assets
http://investor.bacterin.com/phoenix.zhtml?c=234008&p=irol-investorkit
NYSE MKT Deficiency Notice (FROM THEIR LAST 10-Q, DATED 11/7/14)
On May 13, 2013, we received a deficiency notice from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(iii) of the Company Guide with stockholders’ equity of less than $6,000,000 and net losses in five of our most recent fiscal years and Section 1003(a)(ii) with stockholders’ equity of less than $4,000,000 and net losses in three of our four most recent fiscal years. On June 12, 2013 we submitted a plan to regain compliance with the continued listing requirements, and on June 21, 2013 the NYSE MKT informed us of the acceptance of our plan and gave us an extension until November 13, 2014 to regain compliance with the continued listing standards. On November 19, 2013, we received another letter from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(i) of the Company Guide with stockholders’ equity of less than $2,000,000 as of September 30, 2013 and net losses in two of three of our most recent fiscal years, and we submitted an amended plan to regain compliance. If we fail to achieve $6,000,000 in shareholder equity by the end of the extension period, our common stock will most likely be delisted from the NYSE MKT. We continue to evaluate various opportunities that may increase our shareholder equity, and we understand there is an appeal process, but as of the date of this filing, we are not in compliance with the NYSE MKT continued listing requirements, and we do not expect to achieve compliance with the NYSE MKT continued listing requirements by November 13, 2014.
https://research.scottrade.com/qnr/uploadhandler/z06a7100azaaba23eee1fd4ea880348acccd1e4f84.htm
Bacterin Receives Delisting Notice From NYSE MKT
Bacterin Receives Delisting Notice From NYSE MKT
BELGRADE, Mont., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE) today announced that the Company received notice that the staff of NYSE Regulation, Inc. has determined to commence proceedings to delist the Company's common stock from the NYSE MKT LLC ("NYSE MKT" or the "Exchange") because the Company did not cure its non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE MKT Company Guide by the end of the maximum 18 month compliance plan period, which expired on November 13, 2014. Therefore, the Company's common stock is subject to delisting from the Exchange.
The Company plans to appeal the delisting determination. The Company's common stock will continue to trade on the NYSE MKT pending the appeal and final determination by the hearing panel.
Undervalued at current levels!!
Glad I was able to pick some shares at 3.10. They need some money at the moment, but company has a decent product and a plan to sell.
Also, some Institutional buying is expected on November 20th conference in New York. It will possibly be over $3.5 due to heavy buying by Institutions.
Wow... this really took a dive. I cashed out in May (for an $18 loss). That's too bad.
$BONE William Blair Maintains Outperform On Bacterin Following Solid 2Q14 Results http://www.smarteranalyst.com/2014/08/14/william-blair-maintains-outperform-on-bacterin-following-solid-2q14-results/
When do we get the NYSE compliant PR?
Nice one I had been BONE digging at so many levels and even more rapidly in the mid 60s
BONE has some nice technicals setting up, the wall street fox covers it here in this post
http://www.thewallstreetfox.com/2014/05/time-to-go-bone-digging.html
If U accumulated all these days (and still can) at various prices from 70s to 63c, you have reason to smile soon ! esp with a $1.42 high recently !
BONE - looking good now
http://finance.yahoo.com/news/bacterin-announces-preclinical-results-osteoselect-113000279.html
63c must have been bottom
Nice... Hoping for $1 now
The 63c 65c were even real nicer places to double down on the buys !
BONE News and Bottoming since the rise to 1.40s
http://finance.yahoo.com/news/bacterin-announces-addition-two-vice-133500062.html
Bacterin Announces the Addition of Two Vice Presidents
Nice levels to pick up more shares below even 77/78 in last few days
A BUY signal too for new comers
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=BONE
No, Others are lurking in the shadows here.
Nice close - I guess my 0.79 and 0.80 buys are looking good so far
I thought I was all alone like a fool at the 79c 80c level
Pl tell me this is teh day I am loaded up since 85c 83c 80c 79c etc
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
151
|
Created
|
03/23/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |